Swiss National Bank’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Swiss National Bank’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-33,200	Closed	-$306K	–	2627
2017 Q1	$306K	Buy	33,200 +6,000	+22%	+$52.7K	﹤0.01%	2482
2016 Q4	$210K	Hold	27,200	–	–	﹤0.01%	2545
2016 Q3	$311K	Buy	27,200 +13,000	+92%	+$151K	﹤0.01%	2478
2016 Q2	$175K	Hold	14,200	–	–	﹤0.01%	2563
2016 Q1	$138K	Buy	14,200 +3,200	+29%	+$37.6K	﹤0.01%	2586
2015 Q4	$248K	Hold	11,000	–	–	﹤0.01%	2541
2015 Q3	$182K	Buy	11,000 +1,800	+20%	+$36.1K	﹤0.01%	2508
2015 Q2	$207K	Buy	9,200 +1,700	+23%	+$41.9K	﹤0.01%	2539
2015 Q1	$193K	Hold	7,500	–	–	﹤0.01%	2488
2014 Q4	$163K	Hold	7,500	–	–	﹤0.01%	2543
2014 Q3	$142K	Hold	7,500	–	–	﹤0.01%	2489
2014 Q2	$175K	Buy	+7,500	New	+$185K	﹤0.01%	2495

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

IHM

Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Swiss National Bank's OMED Position: Q2 2017 in Review

Swiss National Bank sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2017, closing a stake of 33,200 shares — an estimated $306K sold.

Swiss National Bank first reported a position in OMED in Q2 2014 and held it in 12 quarters. The position peaked at $311K in Q3 2016. 68 funds tracked by Wall St. Rank hold OMED as of Q2 2017.

Swiss National Bank reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Swiss National Bank sold 33,200 OncoMed Pharmaceuticals, Inc. shares in Q2 2017, an estimated $306K.
Swiss National Bank first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2014 and held it in 12 quarters.
Swiss National Bank's OncoMed Pharmaceuticals, Inc. position peaked at $311K in Q3 2016.
68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2017.

Based on Swiss National Bank's 13F filing for Q2 2017, filed 9 Aug 2017.